Association Between Self-rating Depression Scores and Total Ghrelin and Adipokine Serum Levels in a Large Population-Based Sample.
CES-D
IDS-SR
adiponectin
depression
ghrelin
leptin
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
03
2022
accepted:
14
04
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Ghrelin and the adipokines leptin and adiponectin have been suggested to be involved in mood and anxiety regulation and to be altered in affective disorders. However, studies investigating the association between ghrelin, leptin and adiponectin and depressive symptomatology are scarce but might contribute to a better understanding of their involvement in mood regulation. We thus aimed investigating the association between depressive symptomatology and total ghrelin as well as leptin and adiponectin serum levels in a large population-based sample. Total serum ghrelin, adiponectin and leptin levels were determined in 1666 subjects of a population-based cross-sectional study ("LIFE"). The Center for Epidemiological Studies Depression Scale (CES-D) and the Inventory of Depressive Symptoms - Self Rating (IDS-SR) were administered. Multiple linear regression analyses were conducted to examine the association between total serum ghrelin, leptin and adiponectin and the intensity of depressive symptoms. In the total sample ( Our study suggests that peripheral levels of ghrelin and adipokines in a cross-sectional study design might not be sufficient to measure their involvement in depression, suggesting that associations are more complex and multi-layered.
Sections du résumé
Background
UNASSIGNED
Ghrelin and the adipokines leptin and adiponectin have been suggested to be involved in mood and anxiety regulation and to be altered in affective disorders. However, studies investigating the association between ghrelin, leptin and adiponectin and depressive symptomatology are scarce but might contribute to a better understanding of their involvement in mood regulation. We thus aimed investigating the association between depressive symptomatology and total ghrelin as well as leptin and adiponectin serum levels in a large population-based sample.
Methods
UNASSIGNED
Total serum ghrelin, adiponectin and leptin levels were determined in 1666 subjects of a population-based cross-sectional study ("LIFE"). The Center for Epidemiological Studies Depression Scale (CES-D) and the Inventory of Depressive Symptoms - Self Rating (IDS-SR) were administered. Multiple linear regression analyses were conducted to examine the association between total serum ghrelin, leptin and adiponectin and the intensity of depressive symptoms.
Results
UNASSIGNED
In the total sample (
Conclusion
UNASSIGNED
Our study suggests that peripheral levels of ghrelin and adipokines in a cross-sectional study design might not be sufficient to measure their involvement in depression, suggesting that associations are more complex and multi-layered.
Identifiants
pubmed: 35633817
doi: 10.3389/fpsyt.2022.891325
pmc: PMC9130496
doi:
Types de publication
Journal Article
Langues
eng
Pagination
891325Informations de copyright
Copyright © 2022 Wittekind, Kratzsch, Biemann, Mergl, Riedel-Heller, Witte, Villringer and Kluge.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Psychoneuroendocrinology. 2008 May;33(4):497-506
pubmed: 18329818
Neuropsychopharmacology. 2005 Jun;30(6):1187-92
pubmed: 15688086
Transl Psychiatry. 2014 Dec 02;4:e486
pubmed: 25463972
Psychosom Med. 2012 Jan;74(1):39-45
pubmed: 22210236
Biol Psychiatry. 2012 Sep 15;72(6):457-65
pubmed: 22521145
Psychoneuroendocrinology. 2022 Jun;140:105728
pubmed: 35305404
Transl Psychiatry. 2020 Aug 27;10(1):303
pubmed: 32855384
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
pubmed: 21896369
World J Biol Psychiatry. 2020 Dec;21(10):748-756
pubmed: 31552785
Nat Neurosci. 2008 Jul;11(7):752-3
pubmed: 18552842
Psychiatr Serv. 2006 Jun;57(6):829-37
pubmed: 16754760
Int J Neuropsychopharmacol. 2015 Oct 05;19(2):
pubmed: 26438799
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Diabetes Complications. 2003 Mar-Apr;17(2):105-7
pubmed: 12614977
Endocrinology. 2015 Oct;156(10):3695-705
pubmed: 26181103
Psychoneuroendocrinology. 2007 Apr;32(3):287-92
pubmed: 17317021
Nature. 1999 Dec 9;402(6762):656-60
pubmed: 10604470
BMC Psychiatry. 2014 Jul 30;14:203
pubmed: 25079305
J Psychiatr Res. 2011 Mar;45(3):421-6
pubmed: 20888580
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
Psychoneuroendocrinology. 2014 Apr;42:1-10
pubmed: 24636496
Depress Anxiety. 2012 Dec;29(12):1043-9
pubmed: 22933451
Clin Biochem. 2009 Jul;42(10-11):1076-81
pubmed: 19272368
Trends Endocrinol Metab. 2022 Jan;33(1):18-35
pubmed: 34750064
Psychoneuroendocrinology. 2018 Nov;97:143-148
pubmed: 30029157
J Clin Endocrinol Metab. 2000 May;85(5):1954-62
pubmed: 10843181
Neuropsychobiology. 2008;57(3):126-30
pubmed: 18552514
Endocr Connect. 2017 Nov;6(8):847-855
pubmed: 29038331
Biol Psychiatry. 2020 Oct 1;88(7):531-540
pubmed: 32912426
PLoS One. 2012;7(10):e46321
pubmed: 23071554
Neuropsychobiology. 2012;66(4):230-6
pubmed: 23095350
Psychiatry Res. 2015 Aug 30;228(3):866-70
pubmed: 26032460
Neuroendocrinology. 2002 Nov;76(5):316-24
pubmed: 12457042
Brain Res. 2012 Sep 14;1473:185-92
pubmed: 22819931
Nat Med. 2006 Apr;12(4):425-32
pubmed: 16582918
BMC Public Health. 2015 Jul 22;15:691
pubmed: 26197779
Trends Endocrinol Metab. 2017 Dec;28(12):843-854
pubmed: 29097101
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):692-697
pubmed: 28911006
JAMA Netw Open. 2020 Aug 3;3(8):e2013946
pubmed: 32816030
Neuroscience. 2011 Apr 28;180:201-11
pubmed: 21303683
Gesundheitswesen. 2005 Nov;67(11):795-802
pubmed: 16308812
Adv Clin Chem. 2018;85:115-147
pubmed: 29655459
Diabetes. 2001 Aug;50(8):1714-9
pubmed: 11473029
Mol Psychiatry. 2020 Jul;25(7):1457-1468
pubmed: 29899546
Med Care. 2008 Mar;46(3):266-74
pubmed: 18388841
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1270-4
pubmed: 17597276
Psychopharmacology (Berl). 2010 Jul;210(4):559-68
pubmed: 20422404
J Clin Psychiatry. 2012 Sep;73(9):1205-11
pubmed: 22687702
Biomedicines. 2021 Dec 24;10(1):
pubmed: 35052718
J Endocrinol Invest. 2012 Jul;35(7):645-8
pubmed: 22183081
Mol Metab. 2015 Mar 21;4(6):437-60
pubmed: 26042199
Physiol Behav. 2017 Jul 1;176:207-213
pubmed: 28267584
Front Psychiatry. 2019 Jan 07;9:734
pubmed: 30666218
Neuropsychobiology. 2009;59(4):199-204
pubmed: 19521111
Psychiatry Clin Neurosci. 2005 Dec;59(6):736-8
pubmed: 16401252
J Psychopharmacol. 2014 Jun;28(6):582-6
pubmed: 24671339
Psychoneuroendocrinology. 2015 Jan;51:47-57
pubmed: 25290346
J Clin Psychiatry. 2010 Aug;71(8):1079-87
pubmed: 20492842
World J Biol Psychiatry. 2022 Feb 17;:1-16
pubmed: 34870540
Mol Psychiatry. 2017 Jan;22(1):127-133
pubmed: 27046644
J Affect Disord. 2022 Jan 1;296:103-110
pubmed: 34600170
J Psychiatr Res. 2012 Aug;46(8):1081-5
pubmed: 22633396
Biol Psychiatry. 2017 Jun 15;81(12):1003-1013
pubmed: 28010876
Lancet. 2012 Mar 17;379(9820):1045-55
pubmed: 22189047
J Child Adolesc Psychopharmacol. 2016 Oct;26(8):733-739
pubmed: 26862938
Psychoneuroendocrinology. 2012 Jul;37(7):948-55
pubmed: 22130479
Psychoneuroendocrinology. 2010 Feb;35(2):297-304
pubmed: 19647945
Neurosci Lett. 2007 Oct 9;426(1):49-53
pubmed: 17884293
Psychoneuroendocrinology. 2018 Nov;97:20-27
pubmed: 30005278
Front Synaptic Neurosci. 2020 Oct 27;12:594484
pubmed: 33192444
Br J Psychiatry. 1999 Apr;174:307-11
pubmed: 10533549
Psychiatry Investig. 2018 Feb;15(2):214-218
pubmed: 29475222
Psychiatry Investig. 2014 Apr;11(2):167-72
pubmed: 24843372
Transl Psychiatry. 2018 Apr 11;8(1):74
pubmed: 29643360
Psychol Med. 2023 May;53(7):2904-2912
pubmed: 35039097
J Affect Disord. 2021 Dec 1;295:1489-1493
pubmed: 34565598
Nat Rev Neurosci. 2022 Feb;23(2):86-103
pubmed: 34893785
Brain Behav Immun. 2021 Jul;95:391-400
pubmed: 33872705